BioMarin Signs License Deal for Fabry Disease Therapy Candidate

10:45 AM EDT, 10/29/2026 (MT Newswires) -- BioMarin Pharmaceutical (BMRN) said Thursday it has signed a licensing deal with GC Biopharma and Hanmi Pharm to develop and commercialize HM15421/GC1134A for Fabry disease. The agreement is for exclusive worldwide rights, excluding South Korea, to the clinical-stage enzyme replacement therapy for Fabry disease, the company said. BioMarin said it will pay $70 million upfront, with an additional $405 million payments upon certain development and commercial milestones, and tiered royalties. Price: 56.70, Change: +0.70, Percent Change: +1.25